127 related articles for article (PubMed ID: 2502486)
41. Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma. A pilot study.
King LA; Downey GO; Potish RA; Adcock LL; Carson LF; Twiggs LB
Cancer; 1991 Jun; 67(11):2867-71. PubMed ID: 2025852
[TBL] [Abstract][Full Text] [Related]
42. Epithelial carcinoma of the ovary: current strategies.
Katz ME; Schwartz PE; Kapp DS; Luikart S
Ann Intern Med; 1981 Jul; 95(1):98-111. PubMed ID: 6787963
[TBL] [Abstract][Full Text] [Related]
43. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
[TBL] [Abstract][Full Text] [Related]
44. Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
Hainsworth JD; Malcolm A; Johnson DH; Burnett LS; Jones HW; Greco FA
Obstet Gynecol; 1983 May; 61(5):619-23. PubMed ID: 6403897
[TBL] [Abstract][Full Text] [Related]
45. Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy.
Bruckner HW; Cohen CJ; Feuer E; Wallach RC; Kabakow B; Holland JF
Obstet Gynecol; 1987 Jan; 69(1):114-20. PubMed ID: 3099235
[TBL] [Abstract][Full Text] [Related]
46. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
47. Present optimal therapy in ovarian cancer.
Abrams J
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):9-12. PubMed ID: 3082643
[No Abstract] [Full Text] [Related]
48. Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.
Green JA; Warenius HM; Errington RD; Myint S; Spearing G; Slater AJ
Br J Cancer; 1988 Nov; 58(5):635-9. PubMed ID: 3219276
[TBL] [Abstract][Full Text] [Related]
49. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
Vogl SE; Pagano M; Davis TE; Einhorn N; Tunca JC; Kaplan BH; Arseneau JC
Cancer Treat Rep; 1982 Jun; 66(6):1285-90. PubMed ID: 6282454
[TBL] [Abstract][Full Text] [Related]
50. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
51. Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group.
Thigpen JT; Blessing JA; Ball H; Hanjani P; Manetta A; Homesley H
Gynecol Oncol; 1988 Nov; 31(3):435-8. PubMed ID: 3141250
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
53. Whole-abdomen radiation in patients with advanced ovarian carcinoma after surgery, chemotherapy, and second-look laparotomy.
Greiner R; Goldhirsch A; Davis BW; Dreher E; Peyer T; Locher G; Neuenschwander H; Joss R; Brunner K; Veraguth P
J Cancer Res Clin Oncol; 1984; 107(2):94-8. PubMed ID: 6715401
[TBL] [Abstract][Full Text] [Related]
54. Salvage radiotherapy for carcinoma of the ovary following chemotherapy.
Cheung AY
Gynecol Oncol; 1988 May; 30(1):15-20. PubMed ID: 3366392
[TBL] [Abstract][Full Text] [Related]
55. Radiation therapy in stage III ovarian cancer following surgery and chemotherapy: prognostic factors, patterns of relapse, and toxicity: a preliminary report.
Arian-Schad KS; Kapp DS; Hackl A; Juettner FM; Leitner H; Porsch G; Lahousen M; Pickel H
Gynecol Oncol; 1990 Oct; 39(1):47-55. PubMed ID: 2227572
[TBL] [Abstract][Full Text] [Related]
56. Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.
Belinson JL; Pretorius RG; McClure M; Ashikaga T
Gynecol Oncol; 1986 Mar; 23(3):304-9. PubMed ID: 3082726
[TBL] [Abstract][Full Text] [Related]
57. Whole abdominal and pelvic irradiation in patients with minimal disease at second-look surgical reassessment for ovarian carcinoma.
Hoskins WJ; Lichter AS; Whittington R; Artman LE; Bibro MC; Park RC
Gynecol Oncol; 1985 Mar; 20(3):271-80. PubMed ID: 3972290
[TBL] [Abstract][Full Text] [Related]
58. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
59. Whole-abdomen radiation therapy in ovarian carcinoma: its role as a salvage therapeutic modality.
Reddy S; Hartsell W; Graham J; Yordan EL; Lee MS; Sarin P; Phillips AK; McIntosh D; Wilbanks G
Gynecol Oncol; 1989 Dec; 35(3):307-13. PubMed ID: 2599465
[TBL] [Abstract][Full Text] [Related]
60. "Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?".
Bruckner HW
Cancer Treat Rep; 1987 Jun; 71(6):666-8. PubMed ID: 3107816
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
